RA-ILD, rheumatoid arthritis-associated interstitial lung disease; SSc, systemic sclerosis.

Avenciguat and nerandomilast are investigational therapies, which are currently not approved in any country for any indication. Boehringer Ingelheim is currently investigating their efficacy and safety profiles.^1,2 

1.  NCT05559580. Available at: https://clinicaltrials.gov/ct2/show/NCT05559580 (accessed May 2024);

2.  NCT05321082. Available at: https://clinicaltrials.gov/study/NCT05321082 (accessed May 2024).